Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94


Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).

Untch M, von Minckwitz G, Gerber B, Schem C, Rezai M, Fasching PA, Tesch H, Eggemann H, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer JU, Hauschild M, Fehm T, Nekljudova V, Loibl S; GBG and the AGO-B Study Group.

J Clin Oncol. 2018 Mar 15:JCO2017759175. doi: 10.1200/JCO.2017.75.9175. [Epub ahead of print]


Primary Cilia Are Dysfunctional in Obese Adipose-Derived Mesenchymal Stem Cells.

Ritter A, Friemel A, Kreis NN, Hoock SC, Roth S, Kielland-Kaisen U, Brüggmann D, Solbach C, Louwen F, Yuan J.

Stem Cell Reports. 2018 Feb 13;10(2):583-599. doi: 10.1016/j.stemcr.2017.12.022. Epub 2018 Jan 27.


Involvement of the oncogene B-cell lymphoma 6 in the fusion and differentiation process of trophoblastic cells of the placenta.

Jasmer B, Muschol-Steinmetz C, Kreis NN, Friemel A, Kielland-Kaisen U, Brüggmann D, Jennewein L, Allert R, Solbach C, Yuan J, Louwen F.

Oncotarget. 2017 Aug 24;8(65):108643-108654. doi: 10.18632/oncotarget.20586. eCollection 2017 Dec 12.


Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years.

Pfitzner BM, Lederer B, Lindner J, Solbach C, Engels K, Rezai M, Dohnal K, Tesch H, Hansmann ML, Salat C, Beer M, Schneeweiss A, Sinn P, Bankfalvi A, Darb-Esfahani S, von Minckwitz G, Sinn BV, Kronenwett R, Weber K, Denkert C, Loibl S.

Mod Pathol. 2017 Dec 22. doi: 10.1038/modpathol.2017.171. [Epub ahead of print]


BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.

van Rossum AGJ, Schouten PC, Weber KE, Nekljudova V, Denkert C, Solbach C, Köhne CH, Thomssen C, Forstbauer H, Hoffmann G, Kohls A, Schmatloch S, Schem C, von Minckwitz G, Karn T, Möbus VJ, Linn SC, Loibl S, Marmé F.

Breast Cancer Res Treat. 2017 Dec;166(3):775-785. doi: 10.1007/s10549-017-4444-9. Epub 2017 Aug 18.


Quantitative and correlative biodistribution analysis of 89Zr-labeled mesoporous silica nanoparticles intravenously injected into tumor-bearing mice.

Kramer L, Winter G, Baur B, Kuntz AJ, Kull T, Solbach C, Beer AJ, Lindén M.

Nanoscale. 2017 Jul 13;9(27):9743-9753. doi: 10.1039/c7nr02050c.


First international consensus conference on standardization of oncoplastic breast conserving surgery.

Weber WP, Soysal SD, El-Tamer M, Sacchini V, Knauer M, Tausch C, Hauser N, Günthert A, Harder Y, Kappos EA, Schwab F, Fitzal F, Dubsky P, Bjelic-Radisic V, Reitsamer R, Koller R, Heil J, Hahn M, Blohmer JU, Hoffmann J, Solbach C, Heitmann C, Gerber B, Haug M, Kurzeder C.

Breast Cancer Res Treat. 2017 Aug;165(1):139-149. doi: 10.1007/s10549-017-4314-5. Epub 2017 Jun 3.


Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer.

Ingold Heppner B, Untch M, Denkert C, Pfitzner BM, Lederer B, Schmitt W, Eidtmann H, Fasching PA, Tesch H, Solbach C, Rezai M, Zahm DM, Holms F, Glados M, Krabisch P, Heck E, Ober A, Lorenz P, Diebold K, Habeck JO, Loibl S.

Clin Cancer Res. 2016 Dec 1;22(23):5747-5754. Epub 2016 May 17.


Characterization of adipose-derived stem cells from subcutaneous and visceral adipose tissues and their function in breast cancer cells.

Ritter A, Friemel A, Fornoff F, Adjan M, Solbach C, Yuan J, Louwen F.

Oncotarget. 2015 Oct 27;6(33):34475-93. doi: 10.18632/oncotarget.5922.


Radiofluorination of PSMA-HBED via Al(18)F(2+) Chelation and Biological Evaluations In Vitro.

Malik N, Baur B, Winter G, Reske SN, Beer AJ, Solbach C.

Mol Imaging Biol. 2015 Dec;17(6):777-85. doi: 10.1007/s11307-015-0844-6.


Prognostic influence of pre-operative C-reactive protein in node-negative breast cancer patients.

Sicking I, Edlund K, Wesbuer E, Weyer V, Battista MJ, Lebrecht A, Solbach C, Grinberg M, Lotz J, Hoffmann G, Rahnenführer J, Hengstler JG, Schmidt M.

PLoS One. 2014 Oct 23;9(10):e111306. doi: 10.1371/journal.pone.0111306. eCollection 2014.


Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.

von Minckwitz G, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer JU, Hauschild M, Fehm T, Nekljudova V, Gerber B; GBG/AGO-B study groups.

Ann Oncol. 2014 Dec;25(12):2363-72. doi: 10.1093/annonc/mdu455. Epub 2014 Sep 15.


Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A''-DTPA-DUPA-Pep.

Baur B, Solbach C, Andreolli E, Winter G, Machulla HJ, Reske SN.

Pharmaceuticals (Basel). 2014 Apr 29;7(5):517-29. doi: 10.3390/ph7050517.


Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44).

Gerber B, von Minckwitz G, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Solbach C, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Nekljudova V, Loibl S, Untch M.

Ann Surg Oncol. 2014 Aug;21(8):2517-24. doi: 10.1245/s10434-014-3606-9. Epub 2014 Apr 18.


Synthesis, characterization, and biodistribution of multiple 89Zr-labeled pore-expanded mesoporous silica nanoparticles for PET.

Miller L, Winter G, Baur B, Witulla B, Solbach C, Reske S, Lindén M.

Nanoscale. 2014 May 7;6(9):4928-35. doi: 10.1039/c3nr06800e.


Ki-67 as an independent prognostic factor in an unselected cohort of patients with ovarian cancer: results of an explorative, retrospective study.

Battista MJ, Mantai N, Sicking I, Cotarelo C, Weyer V, Lebrecht A, Solbach C, Schmidt M.

Oncol Rep. 2014 May;31(5):2213-9. doi: 10.3892/or.2014.3079. Epub 2014 Mar 11.


Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).

Gerber B, Loibl S, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Nekljudova V, Untch M, von Minckwitz G; German Breast Group Investigators.

Ann Oncol. 2013 Dec;24(12):2978-84. doi: 10.1093/annonc/mdt361. Epub 2013 Oct 17.


Influence of additives to the formulation of n.c.a. [¹¹C]PiB on sterile filter performance.

Patt M, Solbach C, Habermann B, Schildan A, Baur B, Sabri O.

Appl Radiat Isot. 2013 Dec;82:289-92. doi: 10.1016/j.apradiso.2013.09.004. Epub 2013 Sep 19.


HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer.

Denkert C, Huober J, Loibl S, Prinzler J, Kronenwett R, Darb-Esfahani S, Brase JC, Solbach C, Mehta K, Fasching PA, Sinn BV, Engels K, Reinisch M, Hansmann ML, Tesch H, von Minckwitz G, Untch M.

Breast Cancer Res. 2013 Feb 7;15(1):R11. doi: 10.1186/bcr3384.


Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients.

Siggelkow W, Boehm D, Gebhard S, Battista M, Sicking I, Lebrecht A, Solbach C, Hellwig B, Rahnenführer J, Koelbl H, Gehrmann M, Marchan R, Cadenas C, Hengstler JG, Schmidt M.

BMC Cancer. 2012 Nov 27;12:562. doi: 10.1186/1471-2407-12-562.


RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy.

Denkert C, Loibl S, Kronenwett R, Budczies J, von Törne C, Nekljudova V, Darb-Esfahani S, Solbach C, Sinn BV, Petry C, Müller BM, Hilfrich J, Altmann G, Staebler A, Roth C, Ataseven B, Kirchner T, Dietel M, Untch M, von Minckwitz G.

Ann Oncol. 2013 Mar;24(3):632-9. doi: 10.1093/annonc/mds339. Epub 2012 Nov 6.


Immunoglobulin kappa C predicts overall survival in node-negative breast cancer.

Chen Z, Gerhold-Ay A, Gebhard S, Boehm D, Solbach C, Lebrecht A, Battista M, Sicking I, Cotarelo C, Cadenas C, Marchan R, Stewart JD, Gehrmann M, Koelbl H, Hengstler JG, Schmidt M.

PLoS One. 2012;7(9):e44741. doi: 10.1371/journal.pone.0044741. Epub 2012 Sep 28.


Radiosynthesis of carbon-11 labeled 6-methyldopamine ([¹¹C]MeDA).

Al-Momani E, Zlatopolskiy BD, Machulla HJ, Reske SN, Solbach C.

Appl Radiat Isot. 2012 Aug;70(8):1475-9. doi: 10.1016/j.apradiso.2012.04.021. Epub 2012 May 1.


A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors.

Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, Boehm D, Gebhard S, Petry I, Lebrecht A, Cadenas C, Marchan R, Stewart JD, Solbach C, Holmberg L, Edlund K, Kultima HG, Rody A, Berglund A, Lambe M, Isaksson A, Botling J, Karn T, Müller V, Gerhold-Ay A, Cotarelo C, Sebastian M, Kronenwett R, Bojar H, Lehr HA, Sahin U, Koelbl H, Gehrmann M, Micke P, Rahnenführer J, Hengstler JG.

Clin Cancer Res. 2012 May 1;18(9):2695-703. doi: 10.1158/1078-0432.CCR-11-2210. Epub 2012 Feb 20.


Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Fehm T, Müller BM, Denkert C, Loibl S, Nekljudova V, Untch M; German Breast Group; Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups.

N Engl J Med. 2012 Jan 26;366(4):299-309. doi: 10.1056/NEJMoa1111065.


Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures.

Karn T, Pusztai L, Holtrich U, Iwamoto T, Shiang CY, Schmidt M, Müller V, Solbach C, Gaetje R, Hanker L, Ahr A, Liedtke C, Ruckhäberle E, Kaufmann M, Rody A.

PLoS One. 2011;6(12):e28403. doi: 10.1371/journal.pone.0028403. Epub 2011 Dec 29.


Prospective randomized comparison of conventional instruments and the Harmonic Focus(®) device in breast-conserving therapy for primary breast cancer.

Böhm D, Kubitza A, Lebrecht A, Schmidt M, Gerhold-Ay A, Battista M, Stewen K, Solbach C, Kölbl H.

Eur J Surg Oncol. 2012 Feb;38(2):118-24. doi: 10.1016/j.ejso.2011.11.003. Epub 2011 Dec 5.


A clinically relevant gene signature in triple negative and basal-like breast cancer.

Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L, Gaetje R, Solbach C, Ahr A, Metzler D, Schmidt M, Müller V, Holtrich U, Kaufmann M.

Breast Cancer Res. 2011 Oct 6;13(5):R97. doi: 10.1186/bcr3035.


Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation.

Karn T, Pusztai L, Ruckhäberle E, Liedtke C, Müller V, Schmidt M, Metzler D, Wang J, Coombes KR, Gätje R, Hanker L, Solbach C, Ahr A, Holtrich U, Rody A, Kaufmann M.

Eur J Cancer. 2012 Jan;48(1):12-23. doi: 10.1016/j.ejca.2011.06.025. Epub 2011 Jul 7.


Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).

von Minckwitz G, Darb-Esfahani S, Loibl S, Huober J, Tesch H, Solbach C, Holms F, Eidtmann H, Dietrich K, Just M, Clemens MR, Hanusch C, Schrader I, Henschen S, Hoffmann G, Tiemann K, Diebold K, Untch M, Denkert C.

Breast Cancer Res Treat. 2012 Apr;132(3):863-70. doi: 10.1007/s10549-011-1621-0. Epub 2011 Jun 12.


Radiosynthesis of a new PSMA targeting ligand ([18F]FPy-DUPA-Pep).

Malik N, Machulla HJ, Solbach C, Winter G, Reske SN, Zlatopolskiy B.

Appl Radiat Isot. 2011 Jul;69(7):1014-8. doi: 10.1016/j.apradiso.2011.03.041. Epub 2011 Apr 8.


Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance.

Karn T, Ruckhäberle E, Hanker L, Müller V, Schmidt M, Solbach C, Gätje R, Gehrmann M, Holtrich U, Kaufmann M, Rody A.

Breast Cancer Res Treat. 2011 Nov;130(2):409-20. doi: 10.1007/s10549-010-1333-x. Epub 2011 Jan 4.


Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial.

von Minckwitz G, Eidtmann H, Loibl S, Blohmer JU, Costa SD, Fasching PA, Kreienberg R, Hilfrich J, Gerber B, Hanusch C, Fehm T, Strumberg D, Solbach C, Nekljudova V, Untch M; German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie-Brust investigators.

Ann Oncol. 2011 Feb;22(2):301-6. doi: 10.1093/annonc/mdq350. Epub 2010 Jul 12.


Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma.

Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, Glatting G, Buck AK, Solbach C, Neumaier B, Reske SN, Mottaghy FM.

Thyroid. 2010 May;20(5):527-33. doi: 10.1089/thy.2009.0342.


Synthesis and evaluation of 18F-fluoroethylated benzothiazole derivatives for in vivo imaging of amyloid plaques in Alzheimer's disease.

Neumaier B, Deisenhofer S, Sommer C, Solbach C, Reske SN, Mottaghy F.

Appl Radiat Isot. 2010 Jun;68(6):1066-72. doi: 10.1016/j.apradiso.2009.12.044. Epub 2010 Jan 4.


C-11 methionine positron emission tomography/computed tomography localizes parathyroid adenomas in primary hyperparathyroidism.

Weber T, Cammerer G, Schick C, Solbach C, Hillenbrand A, Barth TF, Henne-Bruns D, Blagieva R, Böhm BO, Reske SN, Luster M.

Horm Metab Res. 2010 Mar;42(3):209-14. doi: 10.1055/s-0029-1243185. Epub 2009 Dec 14.


Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, von Törne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M, von Minckwitz G.

J Clin Oncol. 2010 Jan 1;28(1):105-13. doi: 10.1200/JCO.2009.23.7370. Epub 2009 Nov 16. Erratum in: J Clin Oncol. 2010 Feb 1;28(4):708.


Clinical relevance of the putative stem cell marker p63 in breast cancer.

Hanker L, Karn T, Ruckhaeberle E, Gaetje R, Solbach C, Schmidt M, Engels K, Holtrich U, Kaufmann M, Rody A.

Breast Cancer Res Treat. 2010 Aug;122(3):765-75. doi: 10.1007/s10549-009-0608-6. Epub 2009 Nov 7.


Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma.

Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, Glatting G, Buck AK, Solbach C, Neumaier B, Reske SN, Mottaghy FM.

Eur J Nucl Med Mol Imaging. 2010 Mar;37(3):484-93. doi: 10.1007/s00259-009-1294-7. Epub 2009 Oct 28.


Data-driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer.

Karn T, Metzler D, Ruckhäberle E, Hanker L, Gätje R, Solbach C, Ahr A, Schmidt M, Holtrich U, Kaufmann M, Rody A.

Breast Cancer Res Treat. 2010 Apr;120(3):567-79. doi: 10.1007/s10549-009-0416-z. Epub 2009 May 20.


T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.

Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, Engels K, Karn T, Kaufmann M.

Breast Cancer Res. 2009;11(2):R15. doi: 10.1186/bcr2234. Epub 2009 Mar 9.


Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics.

Maetzler W, Liepelt I, Reimold M, Reischl G, Solbach C, Becker C, Schulte C, Leyhe T, Keller S, Melms A, Gasser T, Berg D.

Neurobiol Dis. 2009 Apr;34(1):107-12. doi: 10.1016/j.nbd.2008.12.008. Epub 2008 Dec 31.


Loss of Plexin B1 is highly prognostic in low proliferating ER positive breast cancers--results of a large scale microarray analysis.

Rody A, Karn T, Ruckhäberle E, Hanker L, Metzler D, Müller V, Solbach C, Ahr A, Gätje R, Holtrich U, Kaufmann M.

Eur J Cancer. 2009 Feb;45(3):405-13. doi: 10.1016/j.ejca.2008.10.016. Epub 2008 Dec 4.


Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer.

Rody A, Karn T, Ruckhäberle E, Müller V, Gehrmann M, Solbach C, Ahr A, Gätje R, Holtrich U, Kaufmann M.

Breast Cancer Res Treat. 2009 Feb;113(3):457-66. doi: 10.1007/s10549-008-9964-x. Epub 2008 Mar 14.


Anxiety is associated with reduced central serotonin transporter availability in unmedicated patients with unipolar major depression: a [11C]DASB PET study.

Reimold M, Batra A, Knobel A, Smolka MN, Zimmer A, Mann K, Solbach C, Reischl G, Schwärzler F, Gründer G, Machulla HJ, Bares R, Heinz A.

Mol Psychiatry. 2008 Jun;13(6):606-13, 557. doi: 10.1038/ Epub 2008 Feb 12.


[11C]PIB binding in Parkinson's disease dementia.

Maetzler W, Reimold M, Liepelt I, Solbach C, Leyhe T, Schweitzer K, Eschweiler GW, Mittelbronn M, Gaenslen A, Uebele M, Reischl G, Gasser T, Machulla HJ, Bares R, Berg D.

Neuroimage. 2008 Feb 1;39(3):1027-33. Epub 2007 Oct 22.


Synthetic approaches and bio-distribution studies of [11C]methyl-phenidate.

Patt M, Solbach C, Wüllner U, Blocher A, Stahlschmidt A, Gündisch D, Kovar KA, Machulla HJ.

J Pharm Pharm Sci. 2007;10(2):312s-320s.


[11C]Vinblastine syntheses and preliminary imaging in cancer patients.

Solbach C, Patt M, Reimold M, Blocher A, Dohmen BM, Bares R, Zeller KP, Machulla HJ.

J Pharm Pharm Sci. 2007;10(2):266s-276s.


Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity - a [11C]DASB PET study.

Reimold M, Smolka MN, Zimmer A, Batra A, Knobel A, Solbach C, Mundt A, Smoltczyk HU, Goldman D, Mann K, Reischl G, Machulla HJ, Bares R, Heinz A.

J Neural Transm (Vienna). 2007;114(12):1603-9. Epub 2007 Aug 22.


Supplemental Content

Loading ...
Support Center